A

Aurinia Pharmaceuticals
D

AUPH

16.620
USD
0.25
(1.54%)
مغلق
حجم التداول
36,598
الربح لكل سهم
1
العائد الربحي
-
P/E
7
حجم السوق
2,211,310,412
أصول ذات صلة

العنوان: Aurinia Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.